Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
暂无分享,去创建一个
D. Gaudet | D. Rader | C. Ballantyne | R. Rosenson | D. Whitcomb | J. Bergeron | P. Banerjee | E. Kershaw | P. Rubba | P. Moriarty | S. Baum | R. Pordy | M. Ponda | Jian Zhao | C. Gonzaga‐Jauregui | J. Mcginniss | A. Gewitz
[1] L. Tokgözoğlu,et al. Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach. , 2022, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[2] M. Sabatine,et al. Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 , 2022, Circulation.
[3] R. Rosenson,et al. New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4. , 2021, Journal of the American College of Cardiology.
[4] R. Rosenson,et al. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis , 2021, Lipids in Health and Disease.
[5] D. Gaudet,et al. Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. , 2021, Journal of the American College of Cardiology.
[6] R. Rosenson,et al. Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction , 2021, Cardiovascular Drugs and Therapy.
[7] D. Rader,et al. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report , 2021, Arteriosclerosis, thrombosis, and vascular biology.
[8] ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.
[9] D. Gaudet,et al. Evinacumab for Homozygous Familial Hypercholesterolemia. , 2020, The New England journal of medicine.
[10] R. Hegele,et al. Genetics of Hypertriglyceridemia , 2020, Frontiers in Endocrinology.
[11] Jonathan C. Cohen,et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance , 2020, Journal of Lipid Research.
[12] D. Karalis,et al. Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association , 2020, Journal of General Internal Medicine.
[13] R. Hegele,et al. Clinical review on triglycerides , 2019, European heart journal.
[14] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[15] W. Sasiela,et al. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia , 2019, Circulation.
[16] J. Borén,et al. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD , 2019, Current Atherosclerosis Reports.
[17] R. Hegele,et al. Severe hypertriglyceridemia is primarily polygenic. , 2019, Journal of clinical lipidology.
[18] G. Wang,et al. Elevated Serum Triglycerides in the Prognostic Assessment of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies , 2017, Journal of clinical gastroenterology.
[19] D. Gaudet,et al. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. , 2017, The New England journal of medicine.
[20] Tanya M. Teslovich,et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.
[21] J. Danesh,et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.
[22] J. Mckenney,et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.
[23] D. Gaudet,et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. , 2014, Journal of the American College of Cardiology.
[24] P. Talmud,et al. Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets* , 2013, The Journal of Biological Chemistry.
[25] Colin D Johnson,et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus , 2012, Gut.
[26] K. Lowe,et al. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. , 2011, The American journal of cardiology.
[27] Jonathan C. Cohen,et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.
[28] M. Matsuda,et al. Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[29] A. Gotto,et al. Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[30] R. Ramakrishnan,et al. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. , 1997, The Journal of clinical investigation.